Is afamin a potential early biomarker for subsequent development of preeclampsia? A nested case–control study

Çalışkan, Canan Soyer; Çelik, Samettin; Avcı, Bahattin

doi:10.1080/14767058.2020.1818201

Cited by 4 publications

(6 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multivariate regression analysis was performed in 4 PE-related studies [Köningeret al., ( 18 ); Tramontana et al., ( 15 ); Tramontana et al., ( 16 ); Çalışkan et al., ( 19 )]. The meta-regression analysis showed that there was a significant difference in serum afamin levels between pregnant women with PE and healthy pregnant women ( p = 0.015, ES = 3.089, 95% CI: 1.244-7.666) The heterogeneity of the 4 studies was significant ( I 2 = 90.6%), and there was no significant publication bias (t = 3.80, p = 0.063).…”

Section: Resultsmentioning

confidence: 99%

“…Subgroup analysis based on the time of blood collection found that the plasma afamin levels of pregnant women with PE in the first trimester were significantly higher than those in healthy pregnant women (SMD = 0.808, 95% CI: 0.558-1.059); the plasma afamin levels in pregnant women with PE in the second and third trimesters were significantly higher than those in healthy pregnant women (SMD = 0.904, 95% CI: 0.570-1.239) (Figure 7). (19)]. The meta-regression analysis showed that there was a significant difference in serum afamin levels between pregnant women with PE and healthy pregnant women (p = 0.015, ES = 3.089, 95% CI: 1.244-7.666) The heterogeneity of the 4 studies was significant (I 2 = 90.6%), and there was no significant publication bias (t = 3.80, p = 0.063).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Serum afamin levels in predicting gestational diabetes mellitus and preeclampsia: A systematic review and meta-analysis

Fan

Liang

et al. 2023

Front. Endocrinol.

View full text Add to dashboard Cite

ObjectivesThe association between biomarkers and the risk of gestational diabetes mellitus (GDM) or preeclampsia (PE) has been extensively studied. However, there is still a lack of convenient, specific, and sensitive indicators for early identification of GMD and PE. Therefore, we conducted a meta-analysis of published articles to investigate the value of afamin circulating levels in the early diagnosis of GDM and PE.MethodsWe searched the PubMed, Embase, Cochrane Library, and Web of Science databases for English studies published before November 16, 2022, that examined the association between afamin and GDM or PE. In addition, we searched Clinicaltrials.gov for the relevant completed and ongoing clinical trials. Pooled standard mean differences (SMDs) and weighted mean differences (WMDs) with 95% confidence intervals (CIs) were used to compare the levels of afamin in different groups.ResultsEleven studies were included in our analysis (N = 3047 participants: 1195 GDM, 1407 non-GDM, 195 PE, and 250 non-PE). Subgroup analysis based on different blood collection periods found that the plasma afamin levels in pregnant women with GDM in the first trimester were significantly higher than those in healthy pregnant women (SMD = 0.481, 95% CI: 0.280-0.682), but the analysis showed the opposite results in the second and late stages (SMD = 0.292, 95% CI: -0.092-0.676). The plasma afamin levels of pregnant women with PE in the first trimester (SMD = 0.808, 95% CI: 0.558-1.059) and second/third trimesters (SMD = 0.904, 95% CI: 0.570-1.239) were significantly higher than those in healthy pregnant women.ConclusionThe plasma afamin levels in pregnant women with GDM in the first trimester were significantly higher than those in healthy pregnant women, but the analysis showed the opposite results in the second and third trimesters. The plasma afamin levels in pregnant women with PE in the first, second, and third trimesters were significantly higher than those in healthy pregnant women. Additional large-scale prospective studies are desired to verify these findings, and it is recommended that afamin should be included as a routine diagnostic test for women with GDM and PE.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=339171, identifier CRD42022339171.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Serum afamin levels in predicting gestational diabetes mellitus and preeclampsia: A systematic review and meta-analysis

Fan

Liang

et al. 2023

Front. Endocrinol.

View full text Add to dashboard Cite

show abstract

“…Tramontana et al, involving 30 PE patients and Köninger et al, involving 39 PE patients in their studies found that the first-trimester afamin levels were lower in patients in control compared to the PE group 11,12 . Caliskan et al, in a study of 39 PE patients found that PE developed in those who had high second-trimester afamin levels 3 . Our study differs from other studies in that it detects and reveals high levels of afamin in both first and third trimesters.…”

Section: Discussionmentioning

confidence: 98%

“…Vitamin E is an important protective lipophilic antioxidant that protects against oxidative stress during pregnancy and postpartum 4 . Serum afamin concentrations have previously been reported to increase in response to high oxidative stress 3 .…”

Section: Introductionmentioning

confidence: 99%

“…Afamin (also called α-albumin), which is a vitamin E-binding glycoprotein, has been identified as the fourth member of the human albumin gene family after albumin, α-fetoprotein, and vitamin D-binding protein 3 . Vitamin E is an important protective lipophilic antioxidant that protects against oxidative stress during pregnancy and postpartum 4 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of first- and third-trimester afamin levels in preeclampsia

Gülücü

Çelik

Unver

2023

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

OBJECTIVE:The aim of this study was to investigate serum afamin levels in the first and third trimesters in preeclampsia. METHODS: Serum samples from 118 patients in the first and third trimesters were analyzed. Serum samples were collected from pregnant women who had enrolled in the first trimester. Blood was then collected from pregnant women who had developed preeclampsia and from healthy controls in the third trimester. The collected blood samples were resolved for analysis, and serum afamin concentrations were measured in the first and third trimesters. Preeclampsia and healthy controls were compared. RESULTS: There was no significant difference between the control and preeclampsia groups in terms of age, body mass index, and smoking. Afamin levels in the first and third trimesters were higher in the preeclampsia group than in the control group (p<0.05). In the subgroup analysis of the preeclampsia group, afamin levels were higher in the early-onset preeclampsia group than in the late-onset preeclampsia group in the first and third trimesters (p<0.05). In the receiver operating characteristic analysis afamin levels were 96.23 ng/mL in the first trimester and 123.57 ng/mL in the third trimester as cut-off values for preeclampsia. CONCLUSION: Serum afamin levels are useful for predicting preeclampsia in the first trimester in pregnant women and can be used in clinical practice as a supportive biomarker for the diagnosis of preeclampsia in the third trimester. Meta-analyzes are needed to investigate the effect of afamin levels in the prediction and diagnosis of preeclampsia and to determine the cut-off value.

show abstract

Investigation of serum afamin concentration in pregnant women diagnosed with late fetal growth restriction or small for gestational age fetus

Alakbarova,

Kale,

Muhcu

2023

The Journal of Maternal-Fetal & Neonatal Medicine

View full text Add to dashboard Cite

Is afamin a potential early biomarker for subsequent development of preeclampsia? A nested case–control study

Cited by 4 publications

References 13 publications

Serum afamin levels in predicting gestational diabetes mellitus and preeclampsia: A systematic review and meta-analysis

Serum afamin levels in predicting gestational diabetes mellitus and preeclampsia: A systematic review and meta-analysis

Evaluation of first- and third-trimester afamin levels in preeclampsia

Investigation of serum afamin concentration in pregnant women diagnosed with late fetal growth restriction or small for gestational age fetus

Contact Info

Product

Resources

About